US FDA's plan for spending down its biosimilar user fee carryover balance unexpectedly accelerated in FY 2018, forcing the agency to readjust. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
